Advances in LLM: Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma

摘要

Although the majority of patients with Hodgkin lym-phoma attain a complete response with initial combination chemotherapy and/or radiotherapy, 20—40% of patients with newly diagnosed, advanced-stage Hodgkin lym-phoma are refractory to initial therapy or relapse following a response.1'2 The optimal second-line treatment approach for these patients is high-dose chemotherapy followed by autologous stem cell transplantation (SCT).3 However, autologous SCT induces durable long-term remission in approximately half of patients. For the remaining patients, outcomes are poor, with a median survival of 28 months.4 The lack of effective therapies for this relatively young population has been a key unmet need in cancer therapy.